Gianluca Pirozzi

2004–2021 年に発表

51
論文数
21,219
被引用数
45
h 指数
51
i10 指数

被引用数

Gianluca Pirozzi の年別被引用数1982 年: 被引用 1 件1986 年: 被引用 2 件2005 年: 被引用 8 件2006 年: 被引用 4 件2007 年: 被引用 4 件2008 年: 被引用 1 件2009 年: 被引用 3 件2011 年: 被引用 1 件2012 年: 被引用 2 件2013 年: 被引用 11 件2014 年: 被引用 41 件2015 年: 被引用 83 件2016 年: 被引用 134 件2017 年: 被引用 249 件2018 年: 被引用 290 件2019 年: 被引用 1,253 件2020 年: 被引用 1,565 件2021 年: 被引用 1,544 件2022 年: 被引用 1,328 件2023 年: 被引用 1,018 件2024 年: 被引用 1,371 件2025 年: 被引用 698 件2026 年: 被引用 13 件1983〜1985 年は被引用が無いため表示していません1987〜2004 年は被引用が無いため表示していません2010 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,895 件、この内訳の 21.6%イギリス: 引用元論文 637 件、この内訳の 7.2%ドイツ: 引用元論文 593 件、この内訳の 6.7%イタリア: 引用元論文 585 件、この内訳の 6.7%カナダ: 引用元論文 421 件、この内訳の 4.8%中国: 引用元論文 409 件、この内訳の 4.7%日本: 引用元論文 409 件、この内訳の 4.7%フランス: 引用元論文 407 件、この内訳の 4.6%オランダ: 引用元論文 312 件、この内訳の 3.5%スペイン: 引用元論文 290 件、この内訳の 3.3%ベルギー: 引用元論文 232 件、この内訳の 2.6%スイス: 引用元論文 226 件、この内訳の 2.6%
0%21.6%その他 27%

分野

  • Medicine90.2%
  • Immunology and Microbiology5.8%
  • Biochemistry, Genetics and Molecular Biology1.8%
  • Neuroscience1%
  • Health Professions0.2%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • その他0.8%

トピック

  • Asthma and respiratory diseases15.9%
  • Dermatology and Skin Diseases15.5%
  • Allergic Rhinitis and Sensitization12.7%
  • Psoriasis: Treatment and Pathogenesis4.8%
  • Sinusitis and nasal conditions4.5%
  • IL-33, ST2, and ILC Pathways4.5%
  • その他42.1%

共著者

全論文

検索で開く
  1. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,929

  2. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 2,045

  3. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David M. Weinreich, Neil Stahl, George D. Yancopoulos, Leda Mannent - The Lancet 2019 被引用: 1,479

  4. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brad Shumel - The Lancet 2017 被引用: 1,243

  5. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,162

  6. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2018 被引用: 678

  7. Targeting key proximal drivers of type 2 inflammation in disease

    著者: , , , , , - Nature Reviews Drug Discovery 2015 被引用: 746

  8. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Dermatology 2019 被引用: 509

  9. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 被引用: 1,405

  10. Commonality of the IL-4/IL-13 pathway in atopic diseases

    著者: , , - Expert Review of Clinical Immunology 2017 被引用: 479

  11. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

    著者: , , , , , , , , , , , , , , , - The Lancet 2016 被引用: 880

  12. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

    著者: , , , , , , , , , , , , , , - British Journal of Dermatology 2017 被引用: 475

  13. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis

    著者: , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2019 被引用: 451

  14. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 1,312

  15. Conjunctivitis in dupilumab clinical trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2019 被引用: 422

  16. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

    著者: , , , , , , , , , , , , , , , , , , - JAMA 2016 被引用: 785

  17. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

    著者: , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2014 被引用: 469

  18. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2019 被引用: 256

  19. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

    著者: , , , , , , , , , , , , , , - Clinical & Experimental Allergy 2021 被引用: 185

  20. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

    著者: , , , , , , , , , , , , , , , , - British Journal of Dermatology 2019 被引用: 378

  21. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , - JAMA Dermatology 2019 被引用: 206

  22. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , , - Journal of Investigative Dermatology 2019 被引用: 217

  23. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet 2015 被引用: 566

  24. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

    著者: , , , , , , , , , , - Journal of Dermatological Science 2019 被引用: 185